OR WAIT null SECS
June 19, 2024
Article
A survey found individuals may avoid participating in AATD trials because a trial may require them to go off augmentation therapy.
June 18, 2024
Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.
June 10, 2024
Video
Strnad explains key findings from research presented at the EASL Congress regarding noninvasive testing and biomarkers in AATD-LD based on phase 2 fazirsiran clinical trials.
June 05, 2024
May 31, 2024
Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.
May 30, 2024
Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.
May 29, 2024
Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.
May 10, 2024
A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.